Quality of Life in Men Treated With Carbon Ion Therapy for Prostate Cancer

International Journal of Radiation Oncology Biology Physics

Volumn 72, Issue 4, 2008, Pages 1010-1015

  Wakatsuki, Masaru ^a,b   Tsuji, Hiroshi ^b   Ishikawa, Hitoshi ^a   Yanagi, Takeshi ^b   Kamada, Tadashi ^b   Nakano, Takashi ^a   Suzuki, Hiroyoshi ^c   Akakura, Koichiro ^d   Shimazaki, Jun ^c   Tsujii, Hirohiko ^b  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^c CHIBA UNIVERSITY   (Japan)

^d TOKYO KOSEI NENKIN HOSPITAL   (Japan)

Author keywords

Carbon ion therapy; Particle therapy; Prostate cancer; Quality of life; Radiotherapy

Indexed keywords

CARBON; COMPUTER PERIPHERAL EQUIPMENT; HEAVY IONS; INTERFACES (COMPUTER); RADIOTHERAPY; RISK ASSESSMENT;

AFTER-TREATMENT; ANDROGEN DEPRIVATION THERAPIES; CANCER THERAPIES; CARBON ION RADIOTHERAPIES; CARBON ION THERAPY; CARBON IONS; HORMONE THERAPIES; LOCALIZED PROSTATE CANCERS; LOS ANGELES; PARTICLE THERAPY; PROSTATE CANCER; PROSTATE CANCERS; QUALITY OF LIFE; QUALITY OF LIVES; SUBSCALE; UNIVERSITY OF CALIFORNIA;

IONS;

ADULT; AGED; ANDROGEN THERAPY; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; FAMILY; HUMAN; ION THERAPY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; SOCIAL ASPECT; WELLBEING;

CARBON ISOTOPES; HEAVY IONS; HUMANS; JAPAN; MALE; PROSTATIC NEOPLASMS; QUALITY OF LIFE; QUESTIONNAIRES; RECOVERY OF FUNCTION; TREATMENT OUTCOME;

EID: 54049089631     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.02.035     Document Type: Article

References (24)

1. Suzuki M., Kase Y., Yamaguchi H., et al. Relative biological effectiveness for cell-killing effect on various human cell lines irradiated with heavy-ion medical accelerator in Chiba (HIMAC) carbon-ion beams. Int J Radiat Oncol Biol Phys 48 (2000) 241-250
2. Kanai T., Endo M., Minohara S., et al. Biophysical characteristics of HIMAC clinical irradiation system for heavy-ion radiation therapy. Int J Radiat Oncol Biol Phys 44 (1999) 201-210
3. Kanai T., Furusawa Y., Fukutsu K., et al. Irradiation of mixed beam and design of spread-out Bragg peak for heavy-ion radiotherapy. Radiat Res 147 (1997) 78-85
4. Tsujii H., Mizoe J.E., Kamada T., et al. Overview of clinical experiences on carbon ion radiotherapy at NIRS. Radiother Oncol 73 (2004) 41-49
5. Tsujii H., Morita S., Miyamoto T., et al. Preliminary results of phase I/II carbon-ion therapy at the National Institute of Radiological Sciences. J Brachytherapy Int 13 (1997) 41-49
6. Akakura K., Tsujii H., Morita S., et al. Phase I/II clinical trials of carbon ion therapy for prostate cancer. Prostate 58 (2004) 252-258
7. Ishikawa H., Tsuji H., Kamada T., et al. Carbon ion radiation therapy for prostate cancer: Results of a prospective phase II study. Radiother Oncol 81 (2006) 57-64
8. Ishikawa H., Tsuji H., Kamada T., et al. Risk factors of late rectal bleeding after carbon ion therapy for prostate cancer. Int J Radiat Oncol Biol Phys 66 (2006) 1084-1091
9. Tsuji H., Yanagi T., Ishikawa H., et al. Hypofractionated radiotherapy with carbon ion beams for prostate cancer. Int J Radiat Oncol Biol Phys 63 (2005) 1153-1160
10. Litwin M.S., Hays R.D., Fink A., et al. Quality-of-life outcomes in men treated for localized prostate cancer. JAMA 273 (1995) 129-135
11. Albertsen P.C., Aaronson N.K., Muller M.J., et al. Health-related quality of life among patients with metastatic prostate cancer. Urology 49 (1997) 207-216
12. Esper P., Mo F., Chodak G., et al. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology 50 (1997) 920-928
13. Beard C.J., Propert K.J., Rieker P.P., et al. Complications after treatment with external-beam irradiation in early-stage prostate cancer patients: A prospective multiinstitutional outcomes study. J Clin Oncol 15 (1997) 223-229
14. Hanlon A.L., Watkins Bruner D., Peter R., et al. Quality of life in prostate cancer patients treated with three-dimensional conformal radiation therapy: Comparing late bowel and bladder quality of life symptoms to that of the normal population. Int J Radiat Oncol Biol Phys 49 (2001) 51-59
15. Sobin L.H., and Wittekind C. International Union Against Cancer. TNM classification of malignant tumours. 5th ed. (1997), John Wiley & Sons, New York
16. Hinotsu A., Niimi M., Akaza H., et al. [Development of Japanese version of QOL questionnaire for bladder and prostate cancer patients using FACT-Bl and P: Pilot study]. Gan To Kagaku Ryoho 26 (1999) 657-666
17. Litwin M., Hays E., Fink A., et al. The UCLA Prostate Cancer Index: Development, reliability, and validity of a health-related quality of life measure. Med Care 36 (1998) 1002-1012
18. Kakehi Y., Kamoto T., Ogawa O., et al. Development of Japanese version of the UCLA Prostate Cancer Index: A pilot validation study. Int J Clin Oncol 7 (2002) 306-311
19. Monga U., Kerrigan A.J., Thornby J., et al. Longitudinal study of quality of life in patients with localized prostate cancer undergoing radiotherapy. J Rehabil Res Dev 42 (2005) 391-399
20. Feigenberg S., Lee W., Desilvioet M., et al. Health-related quality of life in men receiving prostate brachytherapy on RTOG 98-05. Int J Radiat Oncol Biol Phys 62 (2005) 956-964
21. Dacal K., Sereika S., Greenspan S., et al. Quality of life in prostate cancer patients taking androgen deprivation therapy. J Am Geriatr Soc 54 (2006) 85-90
22. Korfage I., Essink-Bot M., Borsboom G., et al. Five-year follow-up of health-related quality of life after primary treatment of localized prostate cancer. Int J Cancer 116 (2005) 291-296
23. Fiorino C., Sanguineti G., Cozzarini C., et al. Rectal dose-volume constraints in high-dose radiotherapy of localized prostate cancer. Int J Radiat Oncol Biol Phys 57 (2003) 953-962
24. Abdel-Wahab M., Abitbol A., Lewin A., et al. Quality-of-life assessment after hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and paclitaxel (Taxol) in inoperable and/or unresectable head and neck squamous cell carcinoma. Am J Clin Oncol 28 (2005) 359-366